In vivo properties of three human HER2/neu-expressing murine cell lines in immunocompetent mice

Laboratory Animal Science

Volumn 49, Issue 2, 1999, Pages 179-188

  Penichet, Manuel L ^a   Challita, Pia Maria ^c   Shin, Seung Uon ^d   Sampogna, Sharon L ^b   Rosenblatt, Joseph D ^c   Morrison, Sherie L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d Hallym University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; HYBRID PROTEIN; MEMBRANE PROTEIN; ONCOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSDUCTION; IMMUNOCOMPETENCE; IMMUNOHISTOCHEMISTRY; INOCULATION; MOUSE; NONHUMAN; ONCOGENE NEU; SUBCUTANEOUS TISSUE TUMOR; TUMOR CELL LINE; TUMOR GROWTH;

ADENOCARCINOMA; ANIMALS; COLONIC NEOPLASMS; FLOW CYTOMETRY; GENE EXPRESSION; HUMANS; IMMUNOGLOBULIN G; LYMPHOMA; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; RECEPTOR, ERBB-2; T-LYMPHOCYTES; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0032890538     PISSN: 00236764     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Coussens, L., T. L. Yang-Feng, Y. C. Liao, et al. 1985. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230:1132-1139.
2. Akiyama, T., C. Sudo, H. Ogawara, et al. 1986. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 232:1644-1646.
3. Stern, D. F., P.A. Heffernan, and R. A. Weinberg. 1986. p185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity. Mol. Cell. Biol. 6:1729-1740.
4. Slamon, D. J., G. M. Clark, S. G. Wong, et al. 1987. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182.
5. Slamon, D. J., and G. M. Clark. 1988. Amplification of c-erbB-2 and aggressive human breast tumors? Science 240:1795-1798.
6. Slamon, D. J., W. Godolphin, L. A. Jones, et al. 1989. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712.
7. Thor, A. D., L. H. Schwartz, F. C. Koerner, et al. 1989. Analysis Of c-erbB-2 expression in breast carcinomas with clinical follow-up. Cancer Res. 49:7147-7152.
8. Toikkanen, S., H. Helin, J. Isola, et al. 1992. Prognostic significance of Her-2 oncoprotein expression in breast cancer - a 30-year follow-up. J. Clin. Oncol. 10:1044-1048.
9. Hynes, N. E., and D. F. Stern. 1994. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim. Biophys. Acta 1198:165-184.
10. Ravdin, P. M., and G. C. Chamness. 1995. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers - a review. Gene 159:19-27.
11. Carter, P., L. Presta, C. M. Gorman, et al. 1992. Humanization of an anti-P185her2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. USA 89:4285-4289.
12. Baselga, J., D. Tripathy, J. Mendelsohn, et al. 1996. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer [see. comments]. J. Clin. Oncol. 14:737-744.
13. Pegram, M., A. Lipton, R. Pietras, et al. 1995. Phase II study of intravenous recombinant humanized anti-p185 HER-2 monoclonal antibody plus cisplatin in patients with HER-2/neu overexpressing metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 14:106 (Abstr.).
14. Morrison, S. L. Unpublished data.
15. Challita-Eid, P. M., M. L. Penichet, S-U. Shin, et al. 1997. A B7.1-Ab fusion protein retains antibody specificity and ability to activate via the T cell costimulatory pathway. J. Immunol. 160:3419-3426.
16. Challita-Eid, P.M., C. N. Abboud, S. L. Morrison, et al. 1998. A RANTES-antibody fusion protein retains antigen specificity and chemokine function. J. Immunol. 161: 3729-3736.
17. Mule, J. J., S. Shu, S. L. Schwarz, et al. 1984. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin 2. Science 225: 1487-1489.
18. Lafreniere, R., and S. A. Rosenberg. 1986. A novel approach to the generation and identification of experimental hepatic metastases in a murine model. J. Natl. Cancer Inst. 76:309-322.
19. Xiang, R., H. N. Lode, C. S. Dolman, et al. 1997. Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy. Cancer Res. 57:4948-4955.
20. Papa, M. Z., J. C. Yang, J. T. Vetto, et al. 1988. Combined effects of chemotherapy and interleukin 2 in the therapy of mice with advanced pulmonary tumors. Cancer Res. 48: 122-129.
21. Eisenthal, A., H. Kashtan, M. Rabau, et al. 1993. Antitumor effects of recombinant interleukin-6 expressed in eukaryotic cells. Cancer Immunol. Immunother. 36:101-107.
22. Zitvogel, L., H. Tahara, P. D. Robbins, et al. 1995. Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts. J. Immunol. 155:1393-1403.
23. Irvine, K. R., J. B. Rao, S. A. Rosenberg, et al. 1996. Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J. Immunol. 156:238-245.
24. Rao, J. B., R. S. Chamberlain, V. Bronte, et al. 1996. IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression. J. Immunol. 156:3357-3365.
25. Chamberlain, R. S., M. W. Carroll, V. Bronte, et al. 1996. Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines. Cancer Res. 56:2832-2836.
26. Ghose, T., A. Guclu, J. Tai, et al. 1977, Immunoprophylaxis and immunotherapy of EL4 lymphoma. Eur. J. Cancer 13: 925-935.
27. Schmidberger, H., D. J. Buchsbaum, B. R. Blazar, et al. 1991. Radiotherapy in mice with yttrium-90-labeled anti-ly1 monoclonal antibody-therapy of the T-cell lymphoma-E14. Cancer Res. 51:1883-1890.
28. Visseren, M. J., M. Koot, E. I. van der Voort, et al. 1994. Production of interleukin-2 by EL4 tumor cells induces natural killer cell- and T-cell-mediated immunity. J. Immunother. Emphasis Tumor Immunol. 15:119-128.
29. Cotran, R. S., V. Kumar, and S. L. Robbins. 1994. In F. J. Shoen (ed.), Pathologic basis of disease, 5th ed. W. B. Saunders Co., Philadelphia.
30. Kerékgyárt, C., L. Virág, L. Tank, et al. 1996. Strain differences in the cytotoxic activity and TNF production of murine macrophages stimulated by lentinan. Int. J. Immunopharmacol. 18:347-353.
31. Blach-Olszewska, Z., E. Zaczynska, E. Broniarek, et al. 1993. Production of cytokines by mouse peritoneal cells treated with ToÅpa Torf Preparation (TTP): dependence on age and strain of mice. Arch. Immunol. Ther. Exp. (Warsz) 41:81-85.
32. Ratajczak, H. V., P. T. Thomas, R. B. Sothern, et al. 1993. Evidence for genetic basis of seasonal differences in antibody formation between two mouse strains. Chronobiol. Int. 10: 383-394.
33. Becker, J. C., N. Varki, S. D. Gillies, et al. 1996. An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response. Proc. Natl. Acad. Sci. USA 93:7826-7831.
34. Corbett, T. H., D. P. Griswold, B. J. Roberts, et al. 1975. Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res. 35: 2434-2439.
35. Griswold, D. P., and T. H. Corbett. 1975. A colon tumor model for anticancer agent evaluation. Cancer 36:2441-2444.
36. Ghose, T., and A. Guclu. 1974. Cure of a mouse lymphoma with radio-iodinated antibody. Eur. J. Cancer 10:787-792.
37. Hand, P. H., P. F. Robbins, M. L. Salgaller, et al. 1993. Evaluation of human carcinoembryonic-antigen (CEA)-transduced and non-transduced murine tumors as potential targets for anti-CEA therapies. Cancer Immunol. Immunother. 36:65-75.
38. Pupa, S. M., S. Menard, D. Morelli, et al. 1993, The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage. Oncogene 8:2917-2923.
39. Zabrecky, J. R., T. Lam, S. J. McKenzie, et al. 1991. The extracellular domain of P185/Neu is released from the surface of human breast carcinoma cells, Sk-Br-3. J. Biol. Chem. 266:1716-1720.
40. Lin, Y. Z. J., and G. M. Clinton. 1991. A soluble protein related to the Her-2 proto-oncogene product is released from human breast carcinoma cells, Oncogene 6:639-643.
41. Wei, C., E. Storozynsky, A. J. McAdam, et al. 1996. Expression of human prostate-specific antigen (PSA) in a mouse tumor cell line reduces tumorigenicity and elicits PSA-specific cytotoxic T lymphocytes. Cancer Immunol. Immunother. 42:362-368.
42. Altenschimdt, U., E. Klundt, and B. Croner, et al. 1997. Adoptive transfer of in vitro-targeted, activated T lymphocytes results in total tumor regression. J. Immunol. 159:5509-5515.
43. Epstein, M. M., F. Di Rosa, D. Jankovic, et al. 1995. Successful T cell priming in B cell-deficient mice. J. Exp. Med. 182:915-922.
44. Asano, M. S., and R. Ahmed. 1996. CDS T cell memory in B cell-deficient mice. J. Exp. Med. 183:2165-2174.
45. Challita-Eid, M. P. Unpublished data.
46. Kandl, H., L. Seymour, and W. R. Bezwoda. 1994. Soluble c-erbB-2 fragment in serum correlates with disease stage and predicts for shortened survival in patients with early-stage and advanced breast cancer. Br. J. Cancer 70:739-742.